---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267200"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:08:29.935621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025

## Summary
- Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.
- Cash $11M at Sep 30, 2023; plus $10.2M expected from CPRIT grant through 2024, providing runway into 2025.
- Completed dosing in Cohort 4 of Phase 1 ReSPECT-LM trial; new survival data from Phase 2 ReSPECT-GBM to be presented at SNO Nov 2023.
- Appointed Pius Maliakal, Ph.D. as VP of Clinical Operations; transferred CNSide biomarker assay from Biocept.
- Grant revenue $1.2M in Q3 from CPRIT; total grant awards $3M from NIH and $17.6M from CPRIT.

## SEC filing metadata
- accession: 0001193125-23-267200
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/0001193125-23-267200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/d578460d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267200
- JSON: https://secwatch.observer/filing/0001193125-23-267200.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267200.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: net income $(3.2) million, or $(1.00) per share, EPS $(1.00) per share.
  - Period: third quarter ended September 30, 2023
  - Net income: $(3.2) million, or $(1.00) per share
  - EPS: $(1.00) per share
  - Result: reported results
  source text: Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/0001193125-23-267200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.